AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPTHEA LTD

0.600

0.000

Volume:- -

Turnover:- -

Market Cap:820.79M

PE:-2.96

High:0.600

Open:0.600

Low:0.600

Close:0.600

52wk High:1.120

52wk Low:0.590

Shares:1.37B

Float Shares:786.04M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.203

EPS(LYR):-0.133

ROE:-3383.08%

ROA:-79.28%

PB:-2.86

PE(LYR):-4.51

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.85%

Capital Flow

Inflow:

Outflow:

News

Opthea Begins Development Program To Investigate Potential Lymphangioleiomyomatosis Treatment Candidate

MT Newswires Live

Opthea Limited Issues New Options to Directors Under NED Plan

Opthea Limited unveils strategy to target rare lung disease LAM with OPT-302 relaunch

BNY Mellon Cuts Voting Power in Opthea to 6.37%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1770354720000,"preClose":0.6,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"OPTHEA LTD","floatShares":786037192,"shares":1367978173,"eps":-0.202747,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:12:00 AEDT","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.202747,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786037192,"roa":"-79.28%","roe":"-3383.08%","lyrEps":-0.132923,"shares":1367978173,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.59,"pbRate":"-2.86","psRate":"3943.15","week52High":1.12,"institutionHeld":0,"latestPrice":0.6,"eps":-0.202747,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.202747,"open":0.6,"prevYearClose":0.6,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.6,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607065544","title":"Opthea Begins Development Program To Investigate Potential Lymphangioleiomyomatosis Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2607065544","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607065544?lang=en_us&edition=fundamental","pubTime":"2026-01-30 09:16","pubTimestamp":1769735819,"startTime":"0","endTime":"0","summary":"Opthea (ASX:OPT) said it initiated a development program to investigate its OPT-302 treatment candidate for potentially treating lymphangioleiomyomatosis, starting with evaluating the feasibility of n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2593453935","title":"Opthea Limited Issues New Options to Directors Under NED Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2593453935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593453935?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:50","pubTimestamp":1766440238,"startTime":"0","endTime":"0","summary":"Opthea Limited has issued 41,000,000 unquoted options to acquire fully paid ordinary shares to director Ms Katherine Connell. These options, expiring 11 November 2035, were granted under the Non-Executive Directors Share and Option Plan, as approved at the Annual General Meeting on 11 November 2025. No consideration was paid for the options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7bB3lC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2592953786","title":"Opthea Limited unveils strategy to target rare lung disease LAM with OPT-302 relaunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2592953786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592953786?lang=en_us&edition=fundamental","pubTime":"2025-12-17 07:11","pubTimestamp":1765926674,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbsgKJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2589611806","title":"BNY Mellon Cuts Voting Power in Opthea to 6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589611806","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589611806?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:29","pubTimestamp":1765142972,"startTime":"0","endTime":"0","summary":"The Bank of New York Mellon Corporation and its group entities have reported a change in their relevant interest in Opthea Limited, now holding 87,105,313 ordinary shares, representing a voting power of 6.37%. These shares are held as part of Opthea's ADR program, with ADR holders retaining their voting rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL3qdBgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK","LU0130102774.USD","BK7067","LU1571399168.USD","OPT.AU","LU0477156953.USD","LU0648001328.SGD","BK4559","LU0980610538.SGD","LU1201861249.SGD","BK4588","LU0130517989.USD","BK4585","BK4135","LU1699723380.USD","BK7508"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/OPT.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008451}]}}